Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and Jun N-terminal kinase activation - PubMed

Affiliations

• PMID: 10428814
• DOI: 10.1074/jbc.274.32.22414

Free article

Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and Jun N-terminal kinase activation

E Leo et al. J Biol Chem. 1999.

Free article

Abstract

CD40 is a member of the tumor necrosis factor receptor family that mediates a number of important signaling events in B-lymphocytes and some other types of cells through interaction of its cytoplasmic (ct) domain with tumor necrosis factor receptor-associated factor (TRAF) proteins. Alanine substitution and truncation mutants of the human CD40ct domain were generated, revealing residues critical for binding TRAF2, TRAF3, or both of these proteins. In contrast to TRAF2 and TRAF3, direct binding of TRAF1, TRAF4, TRAF5, or TRAF6 to CD40 was not detected. However, TRAF5 could be recruited to wild-type CD40 in a TRAF3-dependent manner but not to a CD40 mutant (Q263A) that selectively fails to bind TRAF3. CD40 mutants with impaired binding to TRAF2, TRAF3, or both of these proteins completely retained the ability to activate NF-kappaB and Jun N-terminal kinase (JNK), implying that CD40 can stimulate TRAF2- and TRAF3-independent pathways for NF-kappaB and JNK activation. A carboxyl-truncation mutant of CD40 lacking the last 32 amino acids required for TRAF2 and TRAF3 binding, CD40(Delta32), mediated NF-kappaB induction through a mechanism that was suppressible by co-expression of TRAF6(DeltaN), a dominant-negative version of TRAF6, but not by TRAF2(DeltaN), implying that while TRAF6 does not directly bind CD40, it can participate in CD40 signaling. In contrast, TRAF6(DeltaN) did not impair JNK activation by CD40(Delta32). Taken together, these findings reveal redundancy in the involvement of TRAF family proteins in CD40-mediated NF-kappaB induction and suggest that the membrane-proximal region of CD40 may stimulate the JNK pathway through a TRAF-independent mechanism.

Similar articles

• CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs.

  Pullen SS, Dang TT, Crute JJ, Kehry MR. Pullen SS, et al. J Biol Chem. 1999 May 14;274(20):14246-54. doi: 10.1074/jbc.274.20.14246. J Biol Chem. 1999. PMID: 10318845

• CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization.

  Pullen SS, Miller HG, Everdeen DS, Dang TT, Crute JJ, Kehry MR. Pullen SS, et al. Biochemistry. 1998 Aug 25;37(34):11836-45. doi: 10.1021/bi981067q. Biochemistry. 1998. PMID: 9718306

• Tumor necrosis factor receptor-associated factors (TRAFs).

  Bradley JR, Pober JS. Bradley JR, et al. Oncogene. 2001 Oct 1;20(44):6482-91. doi: 10.1038/sj.onc.1204788. Oncogene. 2001. PMID: 11607847 Review.

• Tumor Necrosis Factor Receptor-Associated Factor Regulation of Nuclear Factor κB and Mitogen-Activated Protein Kinase Pathways.

  Shi JH, Sun SC. Shi JH, et al. Front Immunol. 2018 Aug 9;9:1849. doi: 10.3389/fimmu.2018.01849. eCollection 2018. Front Immunol. 2018. PMID: 30140268 Free PMC article. Review.

Cited by

• Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation.

  Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S. Urbich C, et al. J Clin Invest. 2001 Nov;108(10):1451-8. doi: 10.1172/JCI13620. J Clin Invest. 2001. PMID: 11714736 Free PMC article.

• TRAF inhibition drives cancer cell apoptosis and improves retinoic acid sensitivity in multiple cancers models.

  Zhong K, Liu X, Ding W, Peng L, Zeng X, Gu Y. Zhong K, et al. Discov Oncol. 2023 Jun 30;14(1):117. doi: 10.1007/s12672-023-00703-5. Discov Oncol. 2023. PMID: 37389738 Free PMC article.

• Differential TRAF3 utilization by a variant human CD40 receptor with enhanced signaling.

  Peters AL, Bishop GA. Peters AL, et al. J Immunol. 2010 Dec 1;185(11):6555-62. doi: 10.4049/jimmunol.1000135. Epub 2010 Nov 1. J Immunol. 2010. PMID: 21041727 Free PMC article.

• The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity.

  Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, Black MA, McDonough WS, Fortin SP, Niska JR, Winkles JA, Cunliffe HE. Willis AL, et al. Mol Cancer Res. 2008 May;6(5):725-34. doi: 10.1158/1541-7786.MCR-08-0005. Mol Cancer Res. 2008. PMID: 18505918 Free PMC article.

• The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation.

  Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. Brown SA, et al. Biochem J. 2003 Apr 15;371(Pt 2):395-403. doi: 10.1042/BJ20021730. Biochem J. 2003. PMID: 12529173 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal